INDIANAPOLIS and SCHLIEREN-ZURICH, Switzerland, Sept. 18, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and ...
Scientists from the University of Bern have reported preclinical data on KiH_E07_79, a designed ankyrin repeat protein (DARPin) consisting of an Fc fusion construct comprising E07, an immunoglobulin E ...
With the aim of developing an effective and more tolerable conditioning for hematopoietic stem cell transplantation (HSCT), researchers from Molecular Partners AG applied the proprietary ankyrin ...